Literature DB >> 12640094

Benefit of folic acid supplementation in parkinsonian patients treated with levodopa.

T Müller, D Woitalla, W Kuhn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12640094      PMCID: PMC1738372          DOI: 10.1136/jnnp.74.4.549

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.

Authors:  Thomas Müller; Wilfried Kuhn
Journal:  Eur J Clin Pharmacol       Date:  2006-04-22       Impact factor: 2.953

2.  Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.

Authors:  D Caccamo; G Gorgone; M Currò; G Parisi; W Di Iorio; C Menichetti; V Belcastro; L Parnetti; A Rossi; F Pisani; R Ientile; P Calabresi
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

3.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

4.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

Review 5.  Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease.

Authors:  Daniel D Truong
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.